翰森製藥(03692.HK)治療腎病貧血藥物新適應症上市許可申請獲藥監局受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

翰森製藥(03692.HK)治療腎病貧血藥物新適應症上市許可申請獲藥監局受理

阿思達克 05-10 09:23

翰森製藥(03692.HK)公布，由其附屬江蘇豪森藥業集團自主研發的1類創新藥「培莫沙(月太)注射液」(原名稱：培化西海馬(月太)注射液)的新適應症上市許可申請，獲國家藥監局受理，擬用於治療未接受促紅細胞生成素治療的非透析慢性腎病患者的貧血。

翰森製藥(03692.HK)

Relevant Stocks

翰森製藥(03692.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

翰森製藥(03692.HK)治療腎病貧血藥物新適應症上市許可申請獲藥監局受理

Services

About Us

Agreement Statement